October 2, 2018

InSysBio announces their participation at Ninth American Conference on Pharmacometrics (ACoP9), to be held October 7th to 10th, 2018, at the Loews Coronado Bay Resort near San Diego, CA. The theme of ACoP9 is “Modeling without Bounds”. InSysBio welcomes visitors at the booth #23.

Dr. Tatiana Karelina, Head of the Neurodegenerative Diseases modeling group at InSysBio will make a presentation “Quantitative systems pharmacology model for amyloid pathology investigation” on Monday, October 8 in framework of session 2a “From translational PKPD models to quantitative system pharmacology in neurodegeneration drug development”.

InSysBio will present four posters:

Tuesday, October 9, PM session:

• T-020: “Quantitative Systems Pharmacology (QSP) Model of Bispecific T-Cell Engaging Antibody Constructs for Acute Myeloid Leukemia Treatment” by Oleg Demin Jr (InSysBio), Svetlana Rubina (InSysBio), Theresa Yuraszeck (Amgen), Khamir Mehta (Amgen), Vaishali Chudasama (Amgen), Matthias Klinger (Amgen Research), Cedric Dos Santos (Amgen), Oleg Demin (InSysBio) and Sergey Ermakov (Amgen)

Wednesday, October 10, AM session:

• W-003: “Semi-Mechanistic Modeling of BRAF and c-MET Inhibitors in the Treatment of Metastatic Melanoma” by Dmitrii Shchelokov and Oleg Demin Jr
• W-043: “Translational quantitative systems pharmacology model of tau pathology in human and mouse for immunotherapy investigation” by Tatiana Karelina and Alexander Stepanov.

Poster W-043 also was chosen to be presented at the additional poster session to be held during QSP social event on Tuesday, October 9 at 5:30 PM.

Wednesday, October 10, PM session:

• W-004: “Identification of parameters of QSP models responsible for observed variability in experimental data” by Galina Kolesova and Oleg Demin

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

Share